Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an update.
Race Oncology has secured $3.22 million through a private placement to fund its HARNESS-1 Phase 1a/b trial for non-small cell lung cancer, combining RC220 with Tagrisso®. The trial, expected to enroll its first patient by early Q1 2026, has received ethical approval, and the funding reflects strong shareholder support, positioning Race Oncology to advance its cancer treatment initiatives.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company focused on cancer care. Its lead asset, RCDS1, is a small molecule anticancer agent targeting cancer growth regulator MYC. The company is advancing RCDS1 for various oncology indications, including acute myeloid leukaemia and non-small cell lung cancer, and is exploring partnerships to enhance patient access globally.
Average Trading Volume: 549,495
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.1M
For detailed information about RAC stock, go to TipRanks’ Stock Analysis page.